Trial Profile
An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Novartis
- 28 Jun 2007 New trial record.